Insider buying last 90 days
No open-market insider purchases were filed for SHC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Sotera Health's stock slipped this week even as the company reported Q3 2026 results that beat expectations, with adjusted earnings of $0.29 per share against a $0.27 forecast, revenue up 4.4% to $325 million, and adjusted EBITDA rising 3.9% to $171 million. Sterigenics grew 8.2% in constant currency despite medical device softness, while Nelson Labs grew 9.2% on regulatory testing demand, and management reaffirmed full-year guidance for constant currency revenue growth of 5.25% to 6.75%. Barclays maintained its Overweight rating while trimming its price target to $20 from $22, and RBC pointed to a free cash flow inflection in 2027 as capital spending on facility upgrades winds down.
The stock closed at $16.44, up 2.7% on the day, sitting between its 50-day average of $18.16 and 200-day average of $16.93, with a 1-month return of -9% and a 3-month return of -14%. The GekkoIndex reads 68.2, placing shares in the Accumulation zone, and the current price sits 17% below the Gekko Fair Value of $19.80.
The next earnings date falls on 23 February 2027, outside a typical 20-trading-day holding window. Smart money data shows one billionaire holder and five trailblazer holders among current positions, though no insider, Congress, or options activity appears in their respective windows. Seasonally, the next 20 trading days have averaged a 0.8% return over 5 years, rising in 3 of them. The consensus among 4 analysts includes 3 buy ratings and 1 sell, with a consensus target of $22.17.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Sotera Health scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
Averages disagree
Close $16.61 sits between the 50-day ($17.96) and 200-day ($16.89) averages, or the averages disagree.
See the chart65.5, Accumulation
Reading 65.5 is in the Accumulation zone.
See the GekkoIndex14.2% below
Price is 14.2% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings+5.7% on average
From this point in the calendar, the next 20 trading days averaged +5.7% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Sotera Health closed at $16.61 on Nov 13, 2026, +2.2% over the past year, inside a 52-week range of $13.09 to $19.85.
Use the left and right arrow keys to read daily values.
Put SHC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Sotera Health provides sterilization, laboratory testing, and advisory work to clients across North America, Europe, and other international markets. Its sterilization methods include gamma and electron beam irradiation as well as ethylene oxide processing, and it is recognized for these treatment services alongside the microbiological and analytical chemistry testing carried out through its Nelson Labs division.
The company also provides specialized consulting aimed at the medical device and biopharmaceutical fields. Its customer base spans medical device makers, pharmaceutical firms, food and agricultural producers, and a range of commercial, advanced, and specialty application industries, reflecting a mix of testing, treatment, and advisory work built around these different client groups.
Sotera Health was incorporated in 2017 under the name Sotera Health Topco, Inc., before taking its present name in October 2020. It is headquartered in Broadview Heights, Ohio, and its shares are listed on the NASDAQ under the ticker SHC.
Sotera Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.5, in the Accumulation zone, down 7.1 points over five sessions.
Down 7.1 points over five sessions, from the Buying zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 50 | −1.4% | −0.2% | ||
| Accumulation (current zone) | 228 | +1.1% | +1.8% | ||
| Neutral | 369 | −0.2% | +1.2% | ||
| Distribution | 51 | +0.4% | −1.4% | ||
| Selling | 4 | Too few readings yet | |||
Average SHC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Sotera Health trades 14.2% below Gekko Fair Value of $19.35, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Sotera Health shares are worth, recalculated every trading day.
$19.35
Gekko Fair Value, Nov 14, 2026
14.2% Undervalued
At the end of Aug 2026 the price was 10.5% below the estimate.
No open-market insider purchases were filed for Sotera Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for SHC in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in SHC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Sotera Health has been buying back its own shares.
From company filings.
6of the funds Gekko tracks hold SHC.
Sotera Health reports on Feb 23, 2027, before the open (100 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 23, 2027
Expected before the open, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 3, 2026 | $0.29 est $0.27 | $324.9M est $319.9M | −7.6% |
| Aug 6, 2026 | $0.26 est $0.24 | $321.4M est $309.7M | +4.9% |
| May 5, 2026 | $0.18 est $0.17 | $280.0M est $270.8M | +2.7% |
| Feb 24, 2026 | $0.26 est $0.24 | $303.4M est $299.5M | −7.6% |
| Nov 4, 2025 | $0.26 est $0.22 | $311.3M est $299.6M | −4.8% |
| Aug 8, 2025 | $0.20 est $0.17 | $294.3M est $305.0M | +25.3% |
| May 1, 2025 | $0.14 est $0.12 | $254.5M est $276.9M | +7.7% |
| Feb 27, 2025 | $0.21 est $0.20 | $290.2M est $259.7M | −8.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Sotera Health is $21.44, +29.1% from the last close, from 4 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 4 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 4 | Barclays | $20 | +20.4% |
| Nov 4 | J.P. Morgan | $15 | −9.7% |
| Nov 3 | RBC Capital | $24 | +44.5% |
| Oct 19 | Piper Sandler | $25 | +50.5% |
| Oct 14 | J.P. Morgan | $17 | +2.3% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Sotera Health averaged +5.7% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.1% | 2 of 5 |
| Next 10 trading days | +0.4% | 2 of 5 |
| Next 15 trading days | +2.1% | 3 of 5 |
| Next 20 trading days | +5.7% | 3 of 5 |
| Next 30 trading days | +7.8% | 4 of 5 |
For scale, SHC’s typical 20-trading-day move in either direction is about 7.5%.
Sotera Health’s market cap is $4.74B, with a P/E ratio of 27.2 and revenue of $1.23B over the last twelve months.
3 headlines about Sotera Health from the past week, newest first, each linking to the publisher.
Sotera Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Sotera Health’s market cap is $4.74B at the Nov 13, 2026 close of $16.61, with 285.6M shares outstanding. The shares trade on a P/E ratio of 27.2.
The consensus analyst 12-month price target for Sotera Health is $21.44, +29.1% from the last close. Of the 4 firms that rated the stock in the last 90 days, 3 rate it a buy, 0 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Sotera Health is undervalued: the Nov 13, 2026 close of $16.61 is 14.2% below Gekko Fair Value of $19.35. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Sotera Health is expected to report on Feb 23, 2027, before the market opens (100 days away). Analysts expect earnings of $0.26 per share on revenue of $317.5M. Sotera Health beat the earnings estimate in 8 of its last 8 reports, moving 8.7% on average across the report.
Sotera Health’s 52-week high is $19.85 and its 52-week low is $13.09; it closed at $16.61 on Nov 13, 2026, +2.2% over the past year. Over the last five years the shares peaked at $24.90 on Jun 6, 2022.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.